Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Clin Oncol
Huvudupphovsmän: Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2018
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://ncbi.nlm.nih.gov/pubmed/30155246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1672
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk